Trial Profile
Benralizumab Regulates Atopic Dermatitis Through Effects on Eosinophils, Basophils and Innate Lymphoid Type 2 Cells
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- 28 Feb 2022 Primary endpoint (Effect of Benralizumab on the number of allergen-induced eosinophils in the skin) has been met, according to Results presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 28 Feb 2022 Results presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 14 Oct 2021 Status changed from recruiting to completed.